Previous close | 10.30 |
Open | 10.35 |
Bid | 10.50 x 300 |
Ask | 10.54 x 100 |
Day's range | 10.34 - 10.57 |
52-week range | 6.01 - 13.14 |
Volume | |
Avg. volume | 572,800 |
Market cap | 742.377M |
Beta (5Y monthly) | 1.15 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.72 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 14.63 |
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024. “Dr. Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: 23rd Annual Needham Virtual Healthcare Conference: Zymeworks’ management will participate in virtual one-on-one meetings and present
Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Initiation of rolling biologics license application (BLA) filing with the FDA for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (US) with anticipated completion of regulatory submission in 1H 2024 by our partner, Jazz PharmaceuticalsInitiation of Phase 3 confirmatory tri